Across TCGA pan-cancer cohorts, LINC02372 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of LINC02372’s most consistent transcriptional readouts.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where LINC02372 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC02372 is over-expressed in tumor.
LIHC are the cancer types where LINC02372 tumor–normal differential expression is most reproducible.